Melatonin in pathogenesis and therapy of cancer

Indian Journal of Medical Sciences

Volumn 60, Issue 12, 2006, Pages 523-535

  Ravindra, T ^a   Lakshmi, N K ^a   Ahuja, Y R ^b  

^a Bhavans New Science College   (India)

^b Vasavi Medical and Research Centre   (India)

Author keywords

Electric and magnetic fields; Free radical scavenger; Light at night; Oncostatic; Pineal gland

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; 5 HYDROXYTRYPTOPHAN; ANGIOGENIC FACTOR; ANTICONVULSIVE AGENT; CISPLATIN; DNA; ENDOTHELIN 1; ETOPOSIDE; FATTY ACID; FREE RADICAL; GONADORELIN DERIVATIVE; GROWTH FACTOR; IMMUNOMODULATING AGENT; INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 2; IRINOTECAN; MELATONIN; N ACETYLSEROTONIN; NEUROHORMONE; PROTEIN P53; SCAVENGER; SEROTONIN; STEROID; TAMOXIFEN; TELOMERASE; TRIPTORELIN; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER INCIDENCE; CHILDHOOD LEUKEMIA; CIRCADIAN RHYTHM; CLINICAL TRIAL; COLON CANCER; DEPRESSION; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG MECHANISM; ELECTRIC FIELD; GENETIC CONSERVATION; HORMONE ACTION; HORMONE RELEASE; HUMAN; HYPOTHERMIA; IMMUNOMODULATION; IMMUNOPATHOLOGY; JET LAG; LEUKEMIA; LIGHT EXPOSURE; LUNG CANCER; MAGNETIC FIELD; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PHOTORECEPTOR; PINEAL BODY; REPRODUCTION; REVIEW; SCAVENGING SYSTEM; SLEEP DISORDER; STRESS;

EID: 33845583857     PISSN: 00195359     EISSN: None     Source Type: Journal    
DOI: 10.4103/0019-5359.28983     Document Type: Review

References (98)

1. Thapan K, Arendt J, Skene DJ. An action spectrum for melatonin supression: Evidence for a novel nonrod, non-cone photoreceptor system in humans. J Physiol 2001;535:261-7.
2. Reier RJ. Pineal melatonin: Cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991;12:151-80.
3. Tamarkin L, Baird CJ, Aimeida OF. Melatonin: A coordinating signal for mammalian reproduction? Science 1985;227:714-20.
4. Tan DX, Manchester LC, Reiter RJ, Qi W, Hanes MA, Farley NJ. High physiological levels of melatonin in bile of mammals. Life Sci 1999;65:2523-9.
5. Oaknin-Bendahan S, Anis Y, Nir I, Zisapel N. Effects of long-term administration of melatonin and a putative antagonist on the ageing rat. Neuroreport 1995;6:785-8.
6. Brown EN, Choe Y, Shanahan TL, Czeisler CA. A mathematical model of diurnal variations in human plasma melatonin levels. Am J Physiol 1997;272:E506-16.
7. Brugger P, Marktl W, Herold M. Impaired nocturnal secretion of melatonin in coronary heart disease. Lancet 1995;345:1408.
8. Tetsuo M, Polinsky RJ, Markey SP, Kopin IJ. Urinary 6-hydroxymelatonin excretion in patients with orthostatic hypotension. J Clin Endocrinol Metab 1981;53:607-10.
9. Fanget F, Claustrat B, Dalery J, Brun J, Terra JL, Marie-Cardine M, et al. Nocturnal plasma melatonin levels in schizophrenic patients. Biol Psychiatr 1989;25:499-501.
10. Almay BG, von Knorring L, Wetterberg L. Melatonin in serum and urine in patients with idiopathic pain syndromes. Psychiatry Res 1987;22:179-91.
11. Mishima K, Tozawa T, Satoh K, Matsumoto Y, Hishikawa Y, Okawa M. Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer's type with disturbed sleep-waking. Biol Psychiatry 1999;45:417-21.
12. Schernhammer ES, Hankinson SE. Urinary melatonin levels and breast cancer risk. J Natl Cancer Inst 2005;97:1084-7.
13. Mandera M. Usefulness of melatonin in the diagnostics and therapy of pineal gland and brain neoplasms. Wiad Lek 2003;56:569-73.
14. Kos-Kudla B, Ostrowska Z, Kozlowski A, Marek B, Ciesielska-Kopacz N, Kudla M, et al. Circadian rhythm of melatonin in patients with colorectal cancer. Neuro Endocrinol Lett 2002;23:239-42.
15. Qin L, Wang X, Duan Q, Chen B, He S. Inhibitory effect of melatonin on the growth of H22 hepatocarcinoma cells by inducing apoptosis. J Huazhong Univ Sci Technolog Med Sci 2004;24:19-21,31.
16. Grin W, Grüberger W. A significant correlation between melatonin deficiency and endometrial cancer. Gynecol Obstet Invest 1998;45:62-5.
17. Sainz RM, Mayo JC, Tan DX, Leon J, Manchester L, Reiter RJ. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Prostate 2005;63:29-43.
18. Pelham RW, Vaughan GM, Sandock KL. Twenty-four hour cycle of melatonin-like substance in the plasma of human males. J Clin Endocrinol Metab 1973;37:341-4.
19. Armstrong SM, Cassone VM, Chesworth MJ, Redman JR, Short RV. Synchronization of mammalian circadian rhythms of melatonin. J Neural Transm Suppl 1986;21:375-94.
20. Skene DJ, Deacon S, Arendt J. Use of melatonin in circadian rhythm disorders and following phase shifts. Acta Neurobiol Exp (Wars) 1996;56:359-62.
21. Dijk DJ, Duffy JF, Riel E, Shanahan TL, Czeisler CA. Ageing and the circadian and homeostatic regulation of human sleep during forced desynchrony of rest, melatonin and temperature rhythms. J Physiol 1999;516:611-27.
22. Cajochen C, Munch M, Knoblauch V, Blatter K, Wirz-Justice A. Age-related changes in the circadian and homeostatic regulation of human sleep. Chronobiol Int 2006;23:461-74.
23. Lewy AJ, Emens JS, Lefler BJ, Yuhas K, Jackman AR. Melatonin entrains free-running blind people according to a physiological dose-response curve. Chronobiol Int 2005;22:1093-106.
24. Broadway J, Arendt J, Folkard S. Bright light phase shifts the human melatonin rhythm during the Antartic winter. Neurosci Lett 1987;79:185-9.
25. Middleton B, Arendt J, Stone BM. Complex effects of melatonin on human circadian rhythms in constant dim light. J Biol Rhythms 1997;12:467-77.
26. Henshaw DL, Reiter RJ. Do magnetic fields increase risk of childhood leukemia via Melatonin disruption? Bioelctromagnetics 2005;7:S86-97.
27. Comperatore CA, Krueger GP. Circadian rhythm desynchronosis, jet lag, shift lag and coping strategies. Occup Med 1990;5:323-41.
28. Hardeland R, Reiter RJ, Poeggeler B, Tan DX. The significance of the metabolism of the neuroho rmone melatonin: Antioxidative protection and formation of bioactive substances. Neurosci Biobehav Rev 1993;17:347-57.
29. Montilla P, Cruz A, Padillo FJ, Tunez I, Gascon F, Munoz MC, et al. Melatonin versus vitamin E as protective treatment against oxidative stress after extra-hepatic bile duct ligation in rats. J Pineal Res 2001;31:138-44.
30. Guttekin F, Delitas N, Yasar S, Kilinc I. In vivo changes in antioxidant systems and of vitamin C and vitamin E on oxidative damage in erythrocytes induced by chlorpyrifos-ehtyl in rats. Arch Toxicol 2001;75:88-96.
31. Montilla P, Tunez I, Munoz MC, Soria JV, Lopez A. Antioxidative effect of melatonin in rat brain oxidative stress induced by adriamycin. Rev Esp Fisiol 1997;53:301-5.
32. Acuna-Castroviejo D, Escames G, Macias M, Munoz Hoyos A, Molina Carballo A, Arauzo M, et al. Cell protective role of melatonin in the brain. J Pineal Res 1995;19:57-63.
33. Vijayalaxmi, Thomas CR Jr, Russel RJ, Herman TS. Melatonin: From basic research to cancer treatment clinics. J Clin Oncol 2002;20:2575-601.
34. Poon AM, Pang SF. Pineal melatonin-immune system interactions. In: Tang PL, Pang SF, Reiter RJ, editors. Melatonin: A universal photoperiodic signal with diverse actions. Basel: Karger; 1996. p. 71-83.
35. Barath P, Csaba G. Histological changes in the lung, thymus and adrenal one and half year after pinealectomy: Short communication. Acta Biol Acad Sci Hung 1974;25:123-5.
36. Rella W, Lapin V. Immunocompetence of pinealectomized and simultaneously pinealectomized and thymectomized rats. Oncology 1976;33:3-6.
37. Guerrero JM, Garcia-Maurino S, Pozo D. Mechanisms involved in the immunomodulatory effects of melatonin on the human immune system, in Bartsch C, Bartsch H, Blask D, editors. The pineal gland and cancer. Springer-Verlag: Heidelberg, Germany; 2001. p. 408-16.
38. Lerchl A. The melatonin hypothesis: An introduction. Wissenschaft. Forschungsgemeinschaft Funk 2002;16:1-20.
39. th European Congress of Gynecology and Obstetrics Organizing Committee: Finland; 1992.
40. Mantovani G, Maccio A, Massa E, Madeddu C. Managing cancer-related anorexia/cachexia. Drugs 2001;61:499-514.
41. Lissoni P, Rovelli F, Malugani F, Bucovec R, Conti A, Maestroni GJ. Anti-angiogenic activity of melatonin in advanced cancer patients. Neuro Endocrinol Lett 2001;22:45-7.
42. Cos S, Fernandez R, Guezmes A, Sanchez-Barcelo EJ. Influence of melatonin on invasive and metastatic properties of mcf-7 human breast cancer cells. Cancer Res 1998;58:4383-90.
43. Hill SM, Blask DE. Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res 1988;48:6121-6.
44. Cini G, Neri B, Pacini A, Cesati V, Sassoli C, Quattrone S, et al. Antiproliferative activity of melatonin by transcriptional inhibition of cyclin D1 expression: A molecular basis for melatonin-induced oncostatic effects. J Pineal Res 2005;39:12-20.
45. Heldmaier G, Hoffmann K. Melatonin stimulates growth of brown adipose tissue. Nature 1974;247:224-5.
46. Guerrero JM, Santana C, Reiter RJ. Type II thyroxine 5′-deiodinase activity in the rat brown adipose tissue, pineal gland, Harderian gland and cerebral cortex: Effect of acute cold exposure and lack of relationship to pineal melatonin synthesis. J Pineal Res 1990;9:159-66.
47. Kennedy SH. Melatonin disturbances in anorexia nervosa and bulimia nervosa. Int J Eat Disord 1994;16:257-65.
48. Pappolla MA, Bozner P, Soto C, Shao H, Robakis NK, Zagorski M, et al. Inhibition of Alzheimer beta-fibrilogenesis by melatonin. J Biol Chem 1998;273:7185-8.
49. Mayo JC, Sainz RM, Tan DX, Antolin I, Rodriguez C, Reiter RJ. Melatonin and Parkinson's disease. Endocrine 2005;27:169-78.
50. Lusardi P, Piazza E, Fogari R. Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: A 24-hour study. Br J Clin Pharmacol 2000;49:423-7.
51. Bonilla E, Valero N, Chacin-Bonilla L, Medina-Leendertz S. Melatonin and viral infections. J Pineal Res 2004;36:73-9.
52. West SK, Oosthuizen JM. Melatonin levels are decreased in rheumatoid arthritis. J Basic Clin Physiol Pharmacol 1992;3:33-40.
53. Cagnoni ML, Lombardi A, Cerinic MC, Dedola GL, Pignone A. Melatonin for treatment of chronic refractory sarcoidosis. Lancet 1995;346:1229-30.
54. Sandyk R, Anastasiadis PG, Anninos PA, Tsagas N. Is postmenopausal osteoporosis related to pineal gland functions? Int J Neurosci 1992;62:215-25.
55. Yi C, Pan X, Yan H, Guo M, Pierpaoli W. Effects of melatonin in age-related macular degeneration. Ann NY Acad Sci 2005;1057:384-92.
56. Weissbluth L, Weissbluth M. Sudden infant death syndrome: A genetically determined impaired maturation of the photoneuroendocrine system. A unifying hypothesis. J Theor Biol 1994;167:13-25.
57. Soszynski P, Stowinska-Srzednicka J, Kasperlik-Zatuska A, Zgliczynski S. Decreased melatonin concentration in Cushing's syndrome. Horm Metab Res 1989;21:673-4.
58. Ozata M, Bulur M, Bingol N, Beyhan Z, Corakci A, Bolu E, et al. Daytime plasma melatonin levels in male hypogonadism. J Clin Endocrinol Metab 1996;81:1877-81.
59. O'Brien IA, Lewin IG, O'Hare JP, Arendt J, Corrall RJ. Abnormal circadian rhythm of melatonin in diabetic autonomic neuropathy. Clin Endocrinol (Oxf) 1986;24:359-64.
60. Manev H, Uz T. Oral melatonin in neurologically disabled children. Lancet 1998;351:1963.
61. Munoz-Hoyos A, Sanchez-Forte M, Molina-Carballo A, Escames G, Martin-Medina E, Reiter RJ, et al. Melatonin's role as an anticonvulsant and neuronal protector: Experimental and clinical evidence. J Child Neurol 1998;13:501-9.
62. Chamberlain RS, Herman BH. A novel biochemical model linking dysfunction in the brain melatonin, proopiomelanocortin peptides and serotonin in autism. Biol Psychiatr 1990;28:773-93.
63. Lissoni P, Chilelli M, Villa S, Cerizza L, Tancini G. Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: A randomized trial. J Pineal Res 2003;35:12-5.
64. Lissoni P, Meregalli S, Fossati V, Paolorossi F, Barni S, Tancini G, et al. A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer. Tumori 1994;80:464-7.
65. Barni S, Lissoni P, Cazzaniga M, Ardizzoia A, Meregalli S, Fossati V, et al. A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates. Oncology 1995;52:243-5.
66. Lissoni P, Barni S, Ardizzoia A, Tancini G, Conti A, Maestroni G. A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms. Cancer 1994;73:699-701.
67. Lissoni P, Barni S, Meregalli S, Fossati V, Cazzaniga M, Esposti D, et al. Modulation of cancer endocrine therapy by melatonin: A phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer 1995;71:854-6.
68. Lissoni P, Meregalli S, Nosetto L, Barni S, Tancini G, Fossati V, et al. Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology 1996;53:43-6.
69. Cerea G, Vaghi M, Ardizzoia A, Villa S, Bucovec R, Mengo S, et al. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: A randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations. Anticancer Res 2003;23:1951-4.
70. Aldeghi R, Lissoni P, Barni S, Ardizzoia A, Tancini G, Piperno A, et al. Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma. Eur J Cancer 1994;30A:167-70.
71. Lissoni P, Barni S, Tancini G, Ardizzoia A, Rovelli F, Cazzaniga M, et al. Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract. Br J Cancer 1993;67:1404-7.
72. Lissoni P, Barni S, Tancini G, Ardizzoia A, Ricci G, Aldeghi R, et al. A randomized study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br J Cancer 1994;69:196-9.
73. Lissoni P, Bolis S, Brivio F, Fumagalli L. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies. Anticancer Res 2000;20:2103-5.
74. Lissoni P, Brivio F, Ardizzoia A, Tancini G, Barni S. Subcutaneous therapy with low-dose interleukin-2 plus the neurohormone melatonin in metastatic gastric cancer patients with low performance status. Tumori 1993;79:401-4.
75. Lissoni P, Cazzaniga M, Tancini G, Scardino E, Musci R, Barni S, et al. Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: Efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone. Eur Urol 1997;31:178-81.
76. Neri B, Fiorelli C, Moroni F, Nicita G, Paoletti MC, Ponchietti R, et al. Modulation of human lymphoblastoid interferon activity by melatonin in metastatic renal cell carcinoma. A phase II study. Cancer 1994;73:3015-9.
77. Lissoni P, Barni S, Tancini G, Mainini E, Piglia F, Maestroni GJ, et al. Immunoendocrine therapy with low-dose subcutaneous interleukin-2 plus melatonin of locally advanced or metastatic endocrine tumors. Oncology 1995;52:163-6.
78. Cagnacci A. Melatonin in relation to physiology in adult humans. J Pineal Res 1996;21:200-13.
79. Nelson RJ, Demas GE. Role of melatonin in mediating seasonal energetic and immunologic adaptations. Brain Res Bull 1997;44:423-30.
80. Mills E, Wu P, Seely D, Guyatt G. Melatonin in the treatment of cancer: A systematic review of randomized controlled trials and meta-analysis. J Pineal Res 2005;39:360-6.
81. Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: Meta-analysis. BMJ 2006;332:385-93.
82. Brainard GC, Hanifin JP, Greeson JM, Byren B, Glickman G, Gerner E, et al. Action spectrum for melatonin regulation in humans: Evidence for a novel circadian photoreceptor. J Neuroscience 2001;21:6405-12.
83. Foster RG, Hankins MW. Non-rod, non-cone photoreception in the vertebrates. Prog Retin Eye Res 2002;21:507-27.
84. Davis S, Kaune WT, Mirick DK, Chen C, Stevens RG. Residential magnetic fields, Light-at-night and nocturnal urinary 6-Sulfatoxymelatonin concentration in women. Am J Epidemiol 2001;154:591-600.
85. Schernhammer ES, Landent F, Speizel FE, Willet, WC, Hunta DJ, Kawachi L, et al. Rotating night shifts and risk of breast cancer in women participating in the nurses health study. J Natl Cancer Inst 2001;93:1563-8.
86. Rosen LA, Barber I, Lyle DB. A 0.5 G, 60 Hz magnetic field suppresses melatonin production in pinealocytes. Bioelectromagnetics 1998;19:123-7.
87. Lewy H, Massot O, Tanitou Y. Magnetic field (50Hz) increases NAT, HIOMT activity and melatonin release through indirect pathway. Int J radiat Biol 2003;79:431-5.
88. Reiter RJ. The indoleamine melatonin as a free radical scavenger, electron donor and antioxidant. In vitro and in vivo studies. Adv Exp Med Biol 1996;398:307-13.
89. Blask DE, Brainard GC, Dauchy RT, Hanifin JP, Davidson LK, Krause JA, et al. Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res 2005;65:11174-84.
90. Hahn RA. Profound bilateral blindness and the incidence of breast cancer. Epidemiology 1991;2:208-10.
91. Feychting M, Österlund B, Ahlbom A. Reduced cancer incidence among the blind. Epidemiology 1998;9:490-4.
92. Verkasalo PK, Pukkala E, Stevens RG, Ojamo M, Rudanko SL. Inverse association between breast cancer incidence and degree of visual impairment in Finland. Br J Cancer 1999;80:1459-60.
93. Löscher W, Mevissen M. Magnetic fields and breast cancer: Experimental studies on the melatonin hypothesis. In: Stevens RG, Wilson BW, Anderson LE, editors. The Melatonin Hypothesis - Breast Cancer and Use of Electric Power. Battelle Press: Columbus; 1997. p. 555-84.
94. Wertheimer N, Leeper E. Electrical wiring configurations and childhood cancer. Am J Epidemiol 1979;109:273-84.
95. Wartenberg D. Residential magnetic fields and childhood leukemia: A meta-analysis. Am J Public Health 1998;88:1787-94.
96. Washburn EP, Orza MJ, Berlin JA, Nicholson WJ, Todd AC, Frumkin H, et al. Residential proximity to electricity transmission and distribution equipment and risk of childhood leukaemia, childhood lymphoma and childhood nervous system tumors: Systematic review, evaluation and meta-analysis. Cancer Causes Control 1994;5:299-309.
97. Greaves M. Childhood leukaemia. BMJ 2002;324:283-7.
98. Vijayalaxmi, Reiter RJ, Herman TS, Meltz ML. Melatonin and radioprotection from genetic damage: In vivo/in vitro studies with human volunteers. Mut Res 1996;371:221-8.